Organon & Co. (OGN) is in Healthcare, Drug Manufacturers - General, based in United States, listed on NYSE. Market cap 3.61B USD. 52-week range 5.69 to 13.80 USD. Trailing P/E 17.6. Data as of 2026-10-09.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent ...